Cancer name Non Small Cell Lung Cancer
Cancer Type NSCLC
Immunotherapy type Immunostimulant OR Targeting Therapy
Treatment SAR
Drugstatus Approved;Investigated
Drugbank ID DB12500
Checkpoints NA
Signature Type Protein
Signature STAT3
Official Symbol STAT3
Mode of action PHOS_D_DOWN
Description for ‘mode of action’:the ‘mode of action’ for signature is composed of three parts: A_B_C. A describes the level at which the corresponding signature changes, it may contain the following values: TRAN(translation), PROT(protein), CE(cell), METH(methylation), AC(acetylation), PHOS(phosphorylation), MU(mutation), SNP(single nucleotide polymorphism), GLYC(glycosylation) and PATH(pathway). B describes the corresponding signature in which cancer immunotherapy condition group has changed, it may contain the following values: R (immunotherapy response group), NR(immunotherapy non-response group), D (Immunotherapy group), ND (No immunotherapy group). C describes the change detail (specific direction) of the corresponding signature, it may contain the following values: UP (High gene/protein expression or increased cellular abundance or enhanced epigenetic modification), DN (Low gene/protein expression or reduced cellular abundance or attenuated epigenetic modifications), LOSS (deletion mutation), GAIN (gain mutation),Other. For example, the search/browse detail result for CD274 was “PROT_R_UP”, it can be interpreted that the protein level of CD274 was upregulated in immunotherapy response individuals.
Experimental Cell lines
Description Based on these results, we further evaluated the effects of SAR on JAK/STAT-dependent signaling in NSCLC cell lines. A549 and NCIH460 NSCLC cells were stimulated with Type II IFN-gamma in combination with increasing doses of SAR and assessed for STAT1 (Y701) and STAT3 (Y705) protein phosphorylation using Western blot analysis. The data demonstrate that SAR suppressed IFN-gamma-induced STAT1 and STAT3 phosphorylation in a dose-dependent manner
PMID 29467274
Title JAK2 Inhibitor SAR302503 Abrogate sPD-L1 Expression and Targets Therapy Resistant Non–small Cell Lung Cancers